CORE--CLINICAL AND RESEARCH

阿尔茨海默病(AD)的持续科学进步依赖于仔细评估的患者和对照研究的可用性。临床研究开发核心的主要目标是通过为患有记忆疾病的患者提供基本的诊断评估，促进布莱恩发展研究中心的遗传家系研究和其他多学科努力。自1990年以来，我们已经在布莱恩ADRC的神经疾病诊所(NDC)评估了5000多名新患者。我们计划将重点放在对AD和其他相关痴呆患者的持续高质量评估和治疗上。我们还提出了继续为社区中的老年、非裔美国人和其他有色人种发展我们的多元文化临床服务的方法。确定AD和其他迟发性痴呆的遗传学研究的家系。该中心有超过75个家庭登记，其中有多个AD的证据并经尸检确认。我们计划继续开发和评估更多的信息丰富的家庭。我们还打算与杜克人类遗传学中心(DCHG)一起，使用同胞对分析的新遗传方法来研究AD患者的未受影响的兄弟姐妹，以努力识别其他易感基因。继续在布莱恩ADRC尸检计划中积极登记选定的患者和正常对照。目前，我们每年至少进行70次尸检，跟踪观察100多名AD患者和大约200名非痴呆对照。在授予期间，我们将继续我们目前的登记和临床评估做法，但我们也将做出强有力的重点努力，增加少数族裔参加尸检计划的正常对照和痴呆症方案。促进阿尔茨海默病的临床研究。临床核心将继续是布莱恩ADRC研究研究的资源，外部研究将继续通过对认知正常、AD风险增加的受试者进行系统的纵向研究来确定最早的AD临床表型。

The continuing scientific progress in Alzheimer's disease (AD) relies on the availability of carefully evaluated patients and controls for study. The main goal of the Clinical Research Development Core is to facilitate genetic family studies and other multi-disciplinary efforts of the Bryan ADRC by providing the basic diagnostic assessment of patients with memory complaints. We have evaluated over 5000 new patients in the Neurological Disorders Clinic (NDC) of the Bryan ADRC since 1990. We plan to focus on continued high-quality evaluation and treatment of patients with AD and other related dementias. We also propose methods to continue to develop our multi-cultural clinical services to elderly African American and other people of color in the community. Identify families for genetic studies of AD and other late onset dementias. There are over 75 families enrolled in the Center in which there is multi- generated evidence of AD with autopsy confirmation. We plan to continue to develop and evaluate additional informative families. In conjunction with the Duke Center for Human Genetics (DCHG), we also intend to study unaffected siblings of AD patients using new genetic methods of sib-pair analysis, in an effort to identify other susceptibility genes. Continue the active enrollment of selected patients and normal controls in the Bryan ADRC autopsy program. Currently, we conduct at least 70 autopsies per year and follow over 100 patients with AD and approximately 200 non-demented controls. During the grant period we will continue our current enrollment and clinical evaluation practices but we will also make a strong focused effort on increasing minority enrollment in both the normal control and dementia protocols of the autopsy program. Facilitate clinical research studies of Alzheimer's disease. The Clinical Core will continue to be a resource to the research studies of the Bryan ADRC, and to external studies continues to be to define the earliest clinical phenotype of AD through systematic longitudinal study of cognitively normal subjects at enhanced risk of AD.